Drugs / IBI3005
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06418061 | Jan 2025 → Jun 2027 expected | refractory malignant neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07612137 | Jun 2026 → Jun 2027 expected | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06418061 ↗ |
| Modality | Monoclonal antibody | “Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate” NCT06418061 ↗ |